Page last updated: 2024-12-11

technetium tc 99m pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6452753
MeSH IDM0025434

Synonyms (9)

Synonym
pirfotekh
technetium tc 99m pyrophosphate
technetium tc-99m pyrophosphate
52997-54-3
diphosphoric acid, technetium-99tc salt
unii-5l76i61h2b
DB09165
phosphonato phosphate;technetium-99(4+)
Q27262516

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A subsequent pyrophosphate bone scan resulted in no adverse reaction."( Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.
Borchert, RD; Maloney, TR; Murnane, JE; Orzel, JA; Ramos-Gabatin, A, 1986
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Furthermore, the relative influence of each method on the calculated area under the first 7 days of the concentration-time curve (AUC(0-7)) of an IgG in nude mice was assessed using a physiologically based pharmacokinetic model."( Development and evaluation of a novel method for preclinical measurement of tissue vascular volume.
Boswell, CA; Ferl, GZ; Fielder, PJ; Khawli, LA; Marik, J; Mundo, EE; Reich, MP; Schweiger, MG; Theil, FP, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"PYP-SPECT combined with TF-SPECT shows 100% detectability of the AMI lesions, which is significantly higher than other two methods in both experts and beginners."( [Improvement of 99mTc-pyrophosphate scintigraphy in detection of acute myocardial infarction: combined with 99mTc-tetrofosmin].
Higuchi, T; Kawano, M; Kinuya, S; Miyazaki, Y; Murata, Y; Nakajima, K; Taki, J; Tonami, N, 2001
)
0.31
"PYP-SPECT combined with TF-SPECT is a powerful method for detection of AMI."( [Improvement of 99mTc-pyrophosphate scintigraphy in detection of acute myocardial infarction: combined with 99mTc-tetrofosmin].
Higuchi, T; Kawano, M; Kinuya, S; Miyazaki, Y; Murata, Y; Nakajima, K; Taki, J; Tonami, N, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
" Since patients on chemotherapeutic treatment can be submitted to nuclear medicine procedures, we studied the mitomycin-C effect on the bioavailability of the technetium-99m-labelled sodium pyrophosphate (9mTc-PYP) using an animal model."( Evaluation of the effect of mitomycin-C on the bioavailability of technetium-99m-labelled sodium pyrophosphate in mice.
Bernardo-Filho, M; de Mattos, DM; Diré, GF; Freitas, RS; Gomes, ML; Lima, EA; Souza, SM, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" No differences were found in the incidence and dosage requirements for postoperative sedative or vasoactive drugs (morphine, diazepam, propranolol, lidocaine, nitroglycerin and nitroprusside) between the two groups."( Postoperative haemodynamic and pharmacological responses in patients with positive technetium pyrophosphate single-photon emission computed tomography following CABG.
Burns, RJ; Cheng, DC; Chung, A; Chung, F; Feindel, CM, 1992
)
0.28
" The external irradiation dose-response curve indicated a clear radiation-induced inhibitory effect, especially over 10 Gy."( Biological effects and irradiation dose induced in human lymphocytes in vitro by an intracellular radionuclide:99mTc.
Charpentier, B; Chavaudra, J; Fries, D; Galle, P; Meignan, M; Wirquin, E, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (990)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990637 (64.34)18.7374
1990's195 (19.70)18.2507
2000's37 (3.74)29.6817
2010's33 (3.33)24.3611
2020's88 (8.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.61 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (2.16%)5.53%
Reviews69 (6.48%)6.00%
Case Studies229 (21.52%)4.05%
Observational1 (0.09%)0.25%
Other742 (69.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction [NCT05577819]515 participants (Anticipated)Interventional2020-10-02Recruiting
Phase 1 Study to Investigate the Dosimetry and Biodistribution of a Single Intravenous Administration of 99mTc-p5+14 Using SPECT/CT Imaging and Planar Gamma Scintigraphy in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis [NCT05951816]Phase 135 participants (Anticipated)Interventional2023-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]